Gene therapy hope for babies with fatal muscle disease
NCT ID NCT07554924
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a gene therapy called SKG0201 in 11 infants with spinal muscular atrophy (SMA) type I, a severe muscle-weakening disease. The therapy uses a harmless virus to deliver a working copy of the missing SMN1 gene. The study aims to see if it is safe and can improve survival and motor skills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SKG0201 (gene therapy using a harmless virus to deliver a working SMN1 gene)
- What this could lead to
- If successful, this could provide a one-time treatment that improves motor function and survival in infants with SMA type I.
- What could go wrong
- This is an early, small trial (11 infants) testing safety and dosing. Gene therapy carries risks like immune reactions or liver issues, and it may not work for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
Peking University First Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.